Back

Uncovering the potential of circulating tumor DNA for pediatric precision oncology, the INFORM experience

2026-01-22 oncology Title + abstract only
View on medRxiv
Show abstract

Pediatric solid high-risk malignancies mostly lack established molecular biomarkers for early detection, minimal residual disease assessment, or treatment monitoring. Challenges include small patient numbers, limited sample volumes, low tumor mutational burden, and few recurrent alterations. Within the prospective multicenter pediatric precision oncology program INFORM, we collected liquid biopsies from 130 pediatric patients and optimized cfDNA isolation and analysis. Whole-genome, whole-exome,...

Predicted journal destinations